Abstract |
Telithromycin, a recently approved ketolide antibiotic derived from 14-membered macrolides, is active against erythromycin-resistant pneumococci. Telithromycin has enhanced activity in vitro because it binds not only to domain V of ribosomal RNA (like macrolides do) but also to domain II. However, it is not active against streptococci and staphylococci with constitutive macrolide, lincosamide, and streptogramin B resistance. Telithromycin, available in an oral formulation, is approved by the US Food and Drug Administration for use in adults for treatment of (1) community-acquired pneumonia due to Streptococcus pneumoniae (including multidrug-resistant isolates), Haemophilus influenzae, Moraxella catarrhalis, Chlamydia pneumoniae, or Mycoplasma pneumoniae; (2) acute exacerbation of chronic bronchitis due to S. pneumoniae, H. influenzae, or M. catarrhalis; or (3) acute bacterial sinusitis due to S. pneumoniae, H. influenzae, M. catarrhalis, or methicillin- and erythromycin-susceptible Streptococcus aureus. It is not approved for treatment of tonsillitis, pharyngitis, or severe pneumococcal pneumonia. Unique visual adverse effects occurred in 0.27%-2.1% of patients receiving telithromycin therapy. Its enhanced activity against some common respiratory pathogens makes it a valuable addition to the available macrolides.
|
Authors | John R Lonks, Donald A Goldmann |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 40
Issue 11
Pg. 1657-64
(Jun 01 2005)
ISSN: 1537-6591 [Electronic] United States |
PMID | 15889365
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anti-Bacterial Agents
- Ketolides
- telithromycin
|
Topics |
- Anti-Bacterial Agents
(pharmacokinetics, pharmacology, therapeutic use)
- Drug Interactions
- Drug Resistance, Bacterial
- Humans
- Ketolides
(pharmacokinetics, pharmacology, therapeutic use)
- Respiratory Tract Infections
(drug therapy, microbiology)
- Structure-Activity Relationship
|